If History Repeats, Biotech Traders Will Have Fun Next Week. Here's Why.

As if healthcare investors need more reasons to pay attention to next week's J.P. Morgan Healthcare Conference, biotech stocks outperform the S&P 500, historically, during the week of the confab. 

Take a look at the chart included in a preview note published by J.P. Morgan's analysts. The data, itself, come from Bloomberg.

 J.P. Morgan:


We assessed BTK performance relative to the S&P 500 during the week of the J.P. Morgan Healthcare Conference over the past 13 years. We observed that 85% of the time (all but 2 years), the BTK outperformed the S&P 500. From Monday to Friday during the week of the conference, the BTK increased on average by 3.0%, vs. flat S&P 500. Thus, the BTK outperformed the S&P 500 by ~2.9% on average during the week of the conference over the past 13 years

I would have preferred to see the analysis conducted with the more inclusive Nasdaq Biotechnology Index (NBI) because the BTK tracks fewer stocks.

-- Reported by Adam Feuerstein in Boston.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

The Shifting Price Action Continued Today

The Shifting Price Action Continued Today

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)